These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 18046980)

  • 1. [Acute dyskinetic syndrome during chloropromazine treatment of a female patient with CYP2D6 poor metabolism phenotype].
    Beszłej JA; Grzesiak M; Milejski P
    Psychiatr Pol; 2007; 41(4):495-501. PubMed ID: 18046980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone.
    Köhnke MD; Griese EU; Stösser D; Gaertner I; Barth G
    Pharmacopsychiatry; 2002 May; 35(3):116-8. PubMed ID: 12107857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.
    Kobylecki CJ; Jakobsen KD; Hansen T; Jakobsen IV; Rasmussen HB; Werge T
    Neuropsychobiology; 2009; 59(4):222-6. PubMed ID: 19521114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy.
    Crescenti A; Mas S; Gassó P; Parellada E; Bernardo M; Lafuente A
    Clin Exp Pharmacol Physiol; 2008 Jul; 35(7):807-11. PubMed ID: 18346175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of a CYP2D6 poor metabolizer--a patient with schizophrenia on risperidone treatment.
    Bozina N; Jovanović N; Lovrić M; Medved V
    Ther Drug Monit; 2008 Dec; 30(6):748-51. PubMed ID: 18806696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients.
    Lohmann PL; Bagli M; Krauss H; Müller DJ; Schulze TG; Fangerau H; Ludwig M; Barkow K; Held T; Heun R; Maier W; Rietschel M; Rao ML
    Pharmacopsychiatry; 2003; 36(2):73-8. PubMed ID: 12734765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?
    Jürgens G; Rasmussen HB; Werge T; Dalhoff K; Nordentoft M; Andersen SE
    J Clin Psychopharmacol; 2012 Feb; 32(1):100-5. PubMed ID: 22198443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
    Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
    Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism].
    Reggiani K; Vandel P; Haffen E; Sechter D; Bizouard P; Vandel S
    Encephale; 2000; 26(1):62-7. PubMed ID: 10875063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics.
    Nikoloff D; Shim JC; Fairchild M; Patten N; Fijal BA; Koch WH; MacPherson A; Flockhart D; Yoon YR; Yoon JS; Kim YH; Shin JG
    Pharmacogenomics J; 2002; 2(6):400-7. PubMed ID: 12629505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High vulnerability to acute dystonic reactions: a case of antipsychotic exposure and uncontrolled seizure activity.
    Coffey GL; Botts SR; de Leon J
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jun; 29(5):770-4. PubMed ID: 15927338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia.
    Kapitany T; Meszaros K; Lenzinger E; Schindler SD; Barnas C; Fuchs K; Sieghart W; Aschauer HN; Kasper S
    Schizophr Res; 1998 Jul; 32(2):101-6. PubMed ID: 9713905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP 2D6 polymorphism and antipsychotic therapy.
    Plesnicar BK; Dolzan V; Zalar B
    Psychiatr Danub; 2008 Sep; 20(3):369-71. PubMed ID: 18827765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].
    Szewczuk-Bogusławska M; Grzesiak M; Beszłej JA; Kiejna A
    Psychiatr Pol; 2004; 38(6):1093-104. PubMed ID: 15779673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.
    Yagihashi T; Mizuno M; Chino B; Sato Y; Sakuma K; Takebayashi T; Takao T; Kosaki K
    Hum Psychopharmacol; 2009 Jun; 24(4):301-8. PubMed ID: 19387994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug extrapyramidal side-effects or not: is there a dextromethorphan phenotype difference?
    Vandel P; Haffen E; Vandel S; Bonin B; Sechter D; Bizouard P; Dalery J
    Therapie; 2000; 55(3):349-53. PubMed ID: 10967711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients.
    Andreassen OA; MacEwan T; Gulbrandsen AK; McCreadie RG; Steen VM
    Psychopharmacology (Berl); 1997 May; 131(2):174-9. PubMed ID: 9201806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2D6 gene deletion allele in patients with neuroleptic malignant syndrome: preliminary report.
    Kato D; Kawanishi C; Kishida I; Furuno T; Matsumura T; Hasegawa H; Suzuki K; Hirayasu Y
    Psychiatry Clin Neurosci; 2005 Aug; 59(4):504-7. PubMed ID: 16048458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects.
    Zourková A; Hadasová E
    Gen Physiol Biophys; 2003 Mar; 22(1):103-13. PubMed ID: 12870705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.